Renovia Inc., – a company launched to provide a better, safer first line diagnosis and treatment of conditions such as pelvic floor dysfunction. Pelvic floor dysfunction is a condition characterized by a change of bowel movements and sometimes pelvic pains. It is estimated that over 250 million people suffer from it. As a way to arrest this condition with better drugs and diagnostics Renovia Inc., just raised 42 million dollars, where 32 million dollars came from series b investment, and the extra 10 million dollars was a venture debt. This will go in funding their new products for pelvic floor disorders and also producing a new generation of Leva products.
Renovia Inc. is based in Boston Massachusetts USA. It was founded in 2016 by Marc Beer a biotechnologist and pharmaceutical expert who have over 25 years of commercialization experience. The company has seen its first product – Leva. The product is believed to improve the muscles of the pelvic floor, hence treat urine incontinence. Longwood Fund, a healthcare based investor, invested early during round B of the investment. Earlier on, perceptive advisers a firm that invests in groundbreaking innovations in the healthcare sector had led the round of investors.
Renovia Inc. is headed by Marc Beer who is a distinguished biotechnological expert with over 25 years of experience in development and commercialization in diagnostics and pharmaceuticals. Marc founded the company alongside Ramon Iglesias who is the Managing Director and Yolanda Lorie. After launching the company, they successfully agreed to Round A investment with leading venture capitalists. Other leaders include William Dull who is the chief commercial officer. His role includes overseeing commercialization of the company both globally and locally. With over 30 years of experience in life science. As an accomplished executive, William took the post with a view of making the startup company to one of the most iconic healthcare companies of 2018.
Dr. Samantha Pulliam joined Renovia Inc., from the University of North Carolina where she had been an assistant professor in the department of obstetrics and gynecology. She was also the director of urogynecology and pelvic reconstruction surgery. With over 15 years of experience in technological development, Jose Bohorquez has taken the position of chief scientific officer of Renovia Inc. his specialization includes biosensors and medical devices. Lastly, Jessica McKinney, a clinician, and speaker serves as the director of the center for pelvic and women’s health- a program committed to improved physical and maternal health and education. Learn more: https://www.fiercebiotech.com/medtech/renovia-raises-42m-to-fund-digital-health-solutions-for-pelvic-floor-strengthening